SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Quince Therapeutics, Inc. QNCX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Quince Therapeutics, Inc. (QNCX) is a Biotechnology company in the Healthcare sector, currently trading at $1.23. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Valuation: QNCX trades at a trailing Price-to-Earnings (P/E) of -0.1 (S&P 500 average ~25).

Net income is $57M (loss), growing at +0.1%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $15M against $30M equity (Debt-to-Equity (D/E) ratio 0.49, conservative). Current ratio is 6.05 (strong liquidity). Debt-to-assets is 12.9%. Total assets: $114M.

Analyst outlook: 2 / 9 analysts rate QNCX as buy (22%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 45/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 20/100 (Fail), Income ?/100 (Fail).

QNCX SharesGrow Score Overview

59/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 45/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 28/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 0/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — QNCX

QNCX trades at a trailing Price-to-Earnings (P/E) of -0.1 (S&P 500 average ~25). Trailing PEG 0.01. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

QNCX: +0%/yr revenue is, +0.1%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet QNCX: Debt-to-Equity (D/E) ratio 0.49 (conservative), Current ratio is 6.05 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

QNCX: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.

View details →

Analyst outlook: 2 / 9 analysts rate QNCX as buy (22%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

No analyst coverage available for this stock.

Stock Chart & Stats

Market Data

52-Week Range0.08-4.55

Volume2.47M

Avg Volume (30D)10.58M

Market Cap$6.85M

Beta (1Y)1.33

Share Statistics

EPS (TTM)-1.31

Shares Outstanding$43.26M

IPO Date2019-05-09

Employees36

CEODirk Thye

Financial Highlights & Ratios

EBITDA$-56.56M

Net Income$-56.83M

Operating Income$-57.29M

Total Cash$40.78M

Total Debt$14.81M

Net Debt$8.6M

Total Assets$114.48M

Price / Earnings (P/E)-0.9

Analyst Forecast

Rating ConsensusHold

Analysts Covering9

Buy 22% Hold 56% Sell 22%

Company Info

CountryUS

ExchangeNASDAQ Global Select

CurrencyUSD

ISINUS22053A1079

Price Chart

QNCX

Quince Therapeutics, Inc. ↗ · NASDAQ Global Select

Healthcare • Biotechnology

0.08 52WK RANGE 4.55

People Also View

Revolution Medicines, Inc.

Edgewise Therapeutics, Inc.

Mineralys Therapeutics, Inc.

Nuvation Bio Inc.

Assembly Biosciences, Inc.

Ovid Therapeutics Inc.

Third Harmonic Bio, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message